Key result
Following elective stenting, standard clopidogrel and aspirin therapy left 15% of patients with heightened platelet reactivity and 22% with heightened activation at 30 days compared to baseline.
Why the study?
Does standard aspirin and clopidogrel therapy sufficiently reduce platelet reactivity and activation following elective coronary stenting?
Cohort (n=94)
Does standard aspirin and clopidogrel therapy sufficiently reduce platelet reactivity and activation following elective coronary stenting?
A significant proportion of patients undergoing elective stenting on standard aspirin and clopidogrel therapy exhibit persistent heightened platelet reactivity and activation up to 30 days post-procedure, suggesting inadequate platelet inhibition.
Answers are grounded in this paper and cite their sources.
Persistent platelet hyperactivity on standard DAPT after elective stenting warrants caution; leaves open whether tailored regimens improve outcomes in trials.
There is no information on long-term platelet reactivity and activation following elective stenting in patients treated with clopidogrel and aspirin. We measured platelet reactivity and activation at baseline and at 2 h, 24 h, 5 days and 30 days following coronary stenting (n = 94). Patients were treated with the standard aspirin (325 mg) and clopidogrel regimen (300 mg load/75 mg qd). Reactivity was measured by aggregation (5 and 20 microM ADP) and activation was determined by the expression of total and active GP IIb/IIIa. Reactivity and activation were defined as heightened when post-stent aggregation and receptor expression exceeded baseline levels, respectively. Prolonged heightened platelet reactivity was detected by both 5 and 20 microM ADP aggregation. Using 20 microM ADP aggregation, heightened reactivity occurred in 55% of patients at 2 h, 26% at 24 h, 21% at 5 days, and 15% at 30 days post-stenting. A high frequency of heightened platelet activation was detected by both total and active GP IIb/IIIa expression. Using expression of the active GP IIb/IIIa receptor as the marker, activation was greater than baseline in 27% of patients at 2 h, 20% at 24 h, 30% at 5 days, and 22% at 30 days post-stenting. This is the first report demonstrating that a significant percentage of patients receiving standard clopidogrel and aspirin therapy for coronary stenting will have post-drug platelet reactivity and activation above baseline that persists for 30 days after the procedure. These finding suggest insufficient platelet inhibition. The clinical importance of these findings should be further investigated to establish the potential link between insufficient platelet inhibition, stent thrombosis, and restenosis.
No takes yet. Share an insight, caveat, or question.
Gurbel et al. (2004) conducted a cohort in Elective coronary stenting (n=94). Standard aspirin and clopidogrel regimen vs. Baseline was evaluated on Heightened platelet reactivity (by ADP aggregation) and activation (by active GP IIb/IIIa expression) above baseline. Following elective stenting, standard clopidogrel and aspirin therapy left 15% of patients with heightened platelet reactivity and 22% with heightened activation at 30 days compared to baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: